Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
A randomized multi-center study comparing the effect of dasatinib and imatinib on malignant
stem cells in newly diagnosed chronic phase chronic myeloid leukemia (CML) patients. The
research hypothesis is that treatment with dasatinib 100 mg daily (QD) results in greater and
more rapid depletion of the Philadelphia (Ph) -positive stem cell pool within 6 months of
therapy than imatinib 400 mg QD in newly diagnosed CML patients. The study duration is 18
months and approximately 40 patients will be recruited to the study.